← Leaderboards
Mark Onaitis
Va San Diego Healthcare System
$1,390,681
Attributed
$2,416,700
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $415.5K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,416,700 · 3
VA$0 · 2
By mechanism
R01$2,052,039 · 1
R21$359,201 · 1
P41$5,460 · 1
I01$0 · 2
Top collaborators
- David A Cheresh5 shared
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungTumorLung AdenocarcinomaCellsIn VitroIn VivoMutationNon-Small-Cell Lung CarcinomaPathway InteractionsMutantPhenotypeKras2 GeneTumor InitiationNotch ProteinNovel StrategiesAllelesInhibitor/AntagonistGrowthTumor GrowthNeoplastic CellGenetic TranscriptionGenesLungNovel Therapeutics
Grant awards (14)
Role of Sphingolipids in KRAS induced lung adenocarcinoma$0
I01 · FY2025 · VA · contact PI
Role of Sphingolipids in KRAS induced lung adenocarcinoma$0
I01 · FY2024 · VA · contact PI
Exploiting KRAS addiction for lung cancer therapy$407,210
R01 · FY2022 · CA
Exploiting KRAS addiction for lung cancer therapy$415,519
R01 · FY2021 · CA
Proximal Differentiation Therapy for K-Ras-Induced Lung Adenocarcinoma$0
I01 · FY2021 · VA · contact PI
Exploiting KRAS addiction for lung cancer therapy$414,424
R01 · FY2020 · CA
Proximal Differentiation Therapy for K-Ras-Induced Lung Adenocarcinoma$0
I01 · FY2020 · VA · contact PI
Exploiting KRAS addiction for lung cancer therapy$401,777
R01 · FY2019 · CA
Proximal Differentiation Therapy for K-Ras-Induced Lung Adenocarcinoma$0
I01 · FY2019 · VA · contact PI
Exploiting KRAS addiction for lung cancer therapy$413,109
R01 · FY2018 · CA
Proximal Differentiation Therapy for K-Ras-Induced Lung Adenocarcinoma$0
I01 · FY2018 · VA · contact PI
Anti-CTGF Therapy for Squamous Cell Lung Cancer$151,706
R21 · FY2017 · CA · contact PI
Anti-CTGF Therapy for Squamous Cell Lung Cancer$207,495
R21 · FY2016 · CA · contact PI
CELLS OF ORIGIN OF LUNG CANCER$5,460
P41 · FY2009 · RR · contact PI